Celcuity, Inc. (NASDAQ:CELC) Receives $105.25 Consensus PT from Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $105.25.

A number of research firms have issued reports on CELC. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a research report on Monday, October 20th. Wells Fargo & Company started coverage on Celcuity in a research note on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price on the stock. Wolfe Research began coverage on Celcuity in a report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price target on the stock. Stifel Nicolaus increased their price objective on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Craig Hallum lifted their price objective on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th.

Celcuity Trading Down 2.4%

Shares of CELC stock opened at $109.42 on Friday. The business has a 50-day moving average of $104.24 and a 200 day moving average of $72.14. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. Celcuity has a 1-year low of $7.57 and a 1-year high of $120.32. The stock has a market capitalization of $5.06 billion, a PE ratio of -29.81 and a beta of 0.25.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. As a group, sell-side analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. This trade represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at $10,802,700. This represents a 18.18% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 26,900 shares of company stock worth $3,094,917. 15.77% of the stock is currently owned by company insiders.

Institutional Trading of Celcuity

Large investors have recently bought and sold shares of the company. Apis Capital Advisors LLC bought a new position in shares of Celcuity in the 3rd quarter worth approximately $38,334,000. UBS Group AG boosted its position in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares in the last quarter. Deerfield Management Company L.P. purchased a new stake in Celcuity in the third quarter worth $36,236,000. Alliancebernstein L.P. raised its holdings in Celcuity by 2,208.6% in the third quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock worth $32,241,000 after purchasing an additional 624,379 shares in the last quarter. Finally, Soleus Capital Management L.P. lifted its position in Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.